Sol-Gel shares get an end-of-year boost from two pivotal phase III studies Dec. 31, 2019 By Lee Landenberger No Comments Positive top-line data from two pivotal phase III studies of acne vulgaris treatment Twyneo from Sol-Gel Technologies Ltd. is doing the stock end-of the-year favors as shares closed up 19% at $17.50 on Tuesday. Read More